Literature DB >> 17631023

Surveillance renal transplant biopsies and subclinical rejection at three months post-transplant in pediatric recipients.

Leonard C Hymes1, Laurence Greenbaum, Sandra G Amaral, Barry L Warshaw.   

Abstract

UNLABELLED: Subclinical acute rejection (SCR) has been increasingly recognized in adult renal transplant recipients with the advent of surveillance biopsies. However, in children, surveillance biopsies are not routinely performed at most centers. Therefore, the incidence, predisposing factors, treatment, and clinical outcomes of SCR remain unclear in children. From August 2004 to December 2005, we performed 36 protocol biopsies at three months post-transplantation. All patients had received induction therapy with basiliximab and were maintained on prednisone, MMF, and tacrolimus. Sixteen cases of SCR were detected by biopsy (44%). Age, gender, race, donor source, or serum creatinine did not discriminate between children with SCR and those with normal biopsies. All cases of SCR were treated with high doses of methylprednisolone. At one yr post-transplant, renal function was similar in children with SCR to those with normal surveillance biopsies (p = 0.62). Because of the high incidence of SCR, the maintenance dose of MMF was increased by 50% in 20 children transplanted after December 2005. This resulted in a significant decline in the incidence of SCR from 44 to 15% (p < 0.05). However, the incidence of polyomavirus (BK) viremia also increased significantly in these children (p < 0.005).
CONCLUSION: A high incidence of SCR was found on surveillance biopsies at three months post-transplant and could not be predicted by age, gender, race, donor source, or serum creatinine. The occurrence of SCR declined significantly by increasing the dose of MMF, but resulted in an increase in BK viremia. We conclude that surveillance biopsies provide valuable information in the management of pediatric renal transplant recipients. Increasing immunosuppression to avoid SCR should be weighed against the risk for infection.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17631023     DOI: 10.1111/j.1399-3046.2007.00705.x

Source DB:  PubMed          Journal:  Pediatr Transplant        ISSN: 1397-3142


  8 in total

1.  24 weeks of valganciclovir prophylaxis in children after renal transplantation: a 4-year experience.

Authors:  Andres F Camacho-Gonzalez; Julie Gutman; Leonard C Hymes; Traci Leong; Joseph A Hilinski
Journal:  Transplantation       Date:  2011-01-27       Impact factor: 4.939

2.  Urinary chemokines CXCL9 and CXCL10 are noninvasive markers of renal allograft rejection and BK viral infection.

Authors:  J A Jackson; E J Kim; B Begley; J Cheeseman; T Harden; S D Perez; S Thomas; B Warshaw; A D Kirk
Journal:  Am J Transplant       Date:  2011-08-03       Impact factor: 8.086

3.  Protocol biopsies in pediatric renal transplantation: a precious tool for clinical management.

Authors:  Federica Zotta; Isabella Guzzo; Federica Morolli; Francesca Diomedi-Camassei; Luca Dello Strologo
Journal:  Pediatr Nephrol       Date:  2018-07-06       Impact factor: 3.714

4.  Antibody-mediated rejection in young kidney transplant recipients: the dilemma of noncompliance and insufficient immunosuppression.

Authors:  Oriol Bestard; Minnie M Sarwal
Journal:  Pediatr Nephrol       Date:  2014-12-11       Impact factor: 3.714

Review 5.  Assessment of renal pathology and dysfunction in children with Fabry disease.

Authors:  Uma Ramaswami; Behzad Najafian; Arrigo Schieppati; Michael Mauer; Daniel G Bichet
Journal:  Clin J Am Soc Nephrol       Date:  2010-01-07       Impact factor: 8.237

6.  Subclinical inflammation phenotypes and long-term outcomes after pediatric kidney transplantation.

Authors:  Michael E Seifert; Megan V Yanik; Daniel I Feig; Vera Hauptfeld-Dolejsek; Elizabeth C Mroczek-Musulman; David R Kelly; Frida Rosenblum; Roslyn B Mannon
Journal:  Am J Transplant       Date:  2018-06-27       Impact factor: 8.086

Review 7.  Treatment strategies to minimize or prevent chronic allograft dysfunction in pediatric renal transplant recipients: an overview.

Authors:  Britta Höcker; Burkhard Tönshoff
Journal:  Paediatr Drugs       Date:  2009       Impact factor: 3.022

Review 8.  The BK virus in renal transplant recipients-review of pathogenesis, diagnosis, and treatment.

Authors:  Vikas R Dharnidharka; Husam A Abdulnour; Carlos E Araya
Journal:  Pediatr Nephrol       Date:  2010-12-15       Impact factor: 3.651

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.